Cosmos Health
Distributes health products through Greek pharmacies while manufacturing and marketing proprietary healthcare brands.
Something off on this page? Send us feedback.
Profile
Distributes pharmaceutical and health products mainly through Greek pharmacy networks, while Cana manufactures for the group and third parties and Sky Premium Life and Mediterranation supply owned brands. Wholesale provides most revenue, making the business financially concentrated in Greece.
Distributes pharmaceuticals, parapharmaceuticals, medical devices, cosmetics, and supplements through Cosmofarm to Greek pharmacies, while Decahedron performs licensed generic and OTC wholesale in the United Kingdom. Wholesale supplies most revenue, tying results closely to Greek pharmacy demand and the lower-margin economics of pharmaceutical distribution.
Manufactures pharmaceuticals, nutraceuticals, cosmetics, biocides, and medical devices at Cana for its own portfolio and third parties. Markets proprietary Sky Premium Life and Mediterranation products alongside other healthcare brands, linking sourcing, distribution, owned products, and manufacturing within one group.
Uses Cloudscreen for AI-assisted drug-repurposing predictions and in-vitro validation support, with disclosed candidates still in development rather than established commercial product lines. Manufacturing and product activities remain subject to extensive government regulation, while drug candidates must progress through preclinical work, clinical trials, regulatory review, and commercialization.
Company facts
Key statistics
Year to date −55.7% · Average volume (30d) 3.2M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026Q2 FY26 | −$0.10 | −$0.10 | 0.0% | $19.0M | $19.3M | +1.7% | −6.58% |
| Aug 17, 2026Q2 FY26 | $0.01 | −$0.10 | −1,100.0% | $19.4M | $19.0M | −2.2% | −5.92% |
| May 21, 2026Q1 FY26 | −$0.06 | −$0.06 | 0.0% | $17.9M | $17.9M | −0.2% | −1.10% |
| May 20, 2026Q1 FY26 | −$0.01 | −$0.33 | −3,200.0% | $18.8M | $19.7M | +4.7% | −10.20% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $13.7M | $14.7M | $17.1M | $19.7M | $17.9M | $19.0M | |
| Gross profit | $2.0M | $1.2M | $2.6M | $2.1M | $1.4M | $1.5M | |
| Operating income | −$833.1K | −$2.6M | −$1.8M | −$11.2M | −$2.2M | −$2.9M | |
| Net income | −$818.1K | −$2.8M | −$5.4M | −$10.1M | −$2.8M | −$6.1M | |
| Diluted EPS | −$0.03 | −$0.10 | −$0.17 | −$0.33 | −$0.06 | −$0.10 | |
| Gross margin | 14.9% | 7.9% | 15.2% | 10.6% | 7.7% | 8.0% | |
| Operating margin | -6.1% | -17.9% | -10.6% | -57.1% | -12.2% | -15.4% |
Fiscal years (4-quarter sums)FY21 $56.2M · FY22 $50.3M · FY23 $53.4M · FY24 $54.4M · FY25 $65.3M
Revenue by product · Q1 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.8M · Total debt $16.0M · Total assets $61.5M · Shareholders' equity $20.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 54.43M · Float 32.49M · 59.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Grigorios Siokas · director, 10 percent owner, officer: Chief Executive Officer | 14.60M | 26.82% | Form 4 | Jul 31, 2026 |
| Bovopoulos Andreas | 3.73M | 10.00% | 13G | Mar 10, 2026 |
| Georgios Terzis · officer: Chief Financial Officer | 2.56M | 4.71% | Form 4 | Jul 30, 2026 |
| Renaissance Technologies LLC | 390.5K | 0.72% | 13F | May 14, 2026 |
| Geode Capital Management, LLC | 318.1K | 0.58% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 30, 2026 | Grigorios Siokas | director, 10 percent owner, officer: Chief Executive Officer | +349,825 | $0.2001 |
| Jul 29, 2026 | Grigorios Siokas | director, 10 percent owner, officer: Chief Executive Officer | +766,284 | $0.1827 |
| Jun 16, 2026 | Georgios Terzis | officer: Chief Financial Officer | +168,135 | $0.2498 |
| Jun 10, 2026 | Grigorios Siokas | director, 10 percent owner, officer: Chief Executive Officer | +701,447 | $0.2281 |
| Jun 11, 2026 | Grigorios Siokas | director, 10 percent owner, officer: Chief Executive Officer | +218,447 | $0.2060 |
Peers
- Cencora
European pharmacy wholesale and private-label pressure.
- Viatris
Generic, branded, and OTC medicines compete for pharmacy demand.
- Herbalife
Nutrition supplements contest consumer wellness demand.
